<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Guanidinoacetate Methyltransferase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Guanidinoacetate Methyltransferase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Guanidinoacetate Methyltransferase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0012999" target="_blank">
                        MONDO:0012999
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Metabolic Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn error of metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by biallelic pathogenic variants in GAMT (19p13.3). GAMT catalyzes the final step of endogenous creatine synthesis by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as the methyl donor. Loss of GAMT activity produces systemic and cerebral creatine depletion together with neurotoxic accumulation of guanidinoacetate in biofluids and brain. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with intellectual disability, severe speech delay, epilepsy, behavioral abnormalities, and movement disorders. Presymptomatic treatment with creatine supplementation, ornithine, and dietary arginine restriction substantially improves outcomes, motivating addition to the US Recommended Uniform Screening Panel in January 2023. Birth prevalence is estimated at 0.5 to 2 per million live births.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">GAMT molecular function deficiency</div>
                
                <div class="item-desc">Biallelic pathogenic variants in GAMT reduce guanidinoacetate methyltransferase catalytic activity.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        GAMT
                        
                    </span>
                    
                </div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."</div>
                
                
                <div class="evidence-explanation">Supports GAMT molecular dysfunction as the initiating defect.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Deficient creatine biosynthesis</div>
                
                <div class="item-desc">Blocked conversion of guanidinoacetate to creatine causes systemic and cerebral creatine depletion, impairing the creatine/phosphocreatine energy shuttle needed for rapid ATP regeneration in high-energy-demand tissues.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        creatine biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006601" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        phosphocreatine metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006603" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders."</div>
                
                
                <div class="evidence-explanation">Confirms cerebral creatine depletion and GAA accumulation as the dual mechanism of disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Guanidinoacetate neurotoxicity</div>
                
                <div class="item-desc">Guanidinoacetate (GAA) accumulates in brain, CSF, blood, and urine due to blocked conversion to creatine. GAA is neurotoxic and may alter inhibitory neurotransmission, compounding the effects of cerebral energy deficiency.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        gamma-aminobutyric acid signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007214" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        basal ganglion
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002420" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders."</div>
                
                
                <div class="evidence-explanation">Confirms GAA accumulation as a contributor to the neurological phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35505663" target="_blank">PMID:35505663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Along with low creatine levels, guanidinoacetic acid (GAA) toxicity has been implicated in the pathophysiology of the disorder."</div>
                
                
                <div class="evidence-explanation">Supports GAA toxicity as a distinct pathophysiological mechanism beyond creatine deficiency alone.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired neuronal energy homeostasis</div>
                
                <div class="item-desc">The creatine/phosphocreatine system serves as a critical ATP buffer and energy shuttle in neurons. Creatine deficiency impairs rapid ATP regeneration during fluctuating energy demands, contributing to neurodevelopmental dysfunction, seizure susceptibility, and disrupted neurite outgrowth and neurotransmission.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        ATP metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046034" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."</div>
                
                
                <div class="evidence-explanation">Cerebral creatine deficiency directly implies impaired neuronal energy homeostasis via loss of the creatine/phosphocreatine shuttle.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35505663" target="_blank">PMID:35505663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Creatine deficiency disorders are inborn errors of creatine metabolism, an energy homeostasis molecule."</div>
                
                
                <div class="evidence-explanation">Explicitly identifies creatine as an energy homeostasis molecule, supporting the energy-deficit mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Deficient_creatine_biosynthesis[&#34;Deficient creatine biosynthesis&#34;]
    Impaired_neuronal_energy_homeostasis[&#34;Impaired neuronal energy homeostasis&#34;]
    GAMT_molecular_function_deficiency[&#34;GAMT molecular function deficiency&#34;]
    Guanidinoacetate_neurotoxicity[&#34;Guanidinoacetate neurotoxicity&#34;]

    GAMT_molecular_function_deficiency --&gt; Deficient_creatine_biosynthesis
    Deficient_creatine_biosynthesis --&gt; Guanidinoacetate_neurotoxicity
    Guanidinoacetate_neurotoxicity --&gt; Impaired_neuronal_energy_homeostasis

    style Deficient_creatine_biosynthesis fill:#dbeafe
    style Impaired_neuronal_energy_homeostasis fill:#dbeafe
    style GAMT_molecular_function_deficiency fill:#dbeafe
    style Guanidinoacetate_neurotoxicity fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(6)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscular hypotonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."</div>
                
                
                <div class="evidence-explanation">Lists hypotonia as an associated feature of untreated GAMT deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36856349" target="_blank">PMID:36856349</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia."</div>
                
                
                <div class="evidence-explanation">Confirms hypotonia among the symptom spectrum.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">6</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Global developmental delay
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                                Global developmental delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001263)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants"</div>
                
                
                <div class="evidence-explanation">Quantifies developmental delay at 44/48 (92%) in the landmark GAMT deficiency cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"84% of the cases expressed a form of developmental delay."</div>
                
                
                <div class="evidence-explanation">Confirms high frequency of developmental delay in a scoping review of 53 cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intellectual disability
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                                Intellectual disability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001249)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The median age at treatment initiation was 25.5 and 39 months in patients with mild and moderate DD/ID, respectively, and 11 years in patients with severe DD/ID."</div>
                
                
                <div class="evidence-explanation">Demonstrates correlation between treatment timing and severity of intellectual disability.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"43% of the cases had intellectual disabilities and mental retardation that affected their learning process; most cases required special care."</div>
                
                
                <div class="evidence-explanation">Supports intellectual disability as a major feature requiring special care.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Delayed speech and language development
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000750" target="_blank">
                                Delayed speech and language development
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000750)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The symptoms and signs are reviewed, emphasising that delayed language development is a particular feature."</div>
                
                
                <div class="evidence-explanation">Identifies delayed language development as a particularly prominent feature of GAMT deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants"</div>
                
                
                <div class="evidence-explanation">Confirms speech/language delay as one of the most affected domains.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13."</div>
                
                
                <div class="evidence-explanation">Quantifies epilepsy at 35/48 (73%) in the landmark cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"68% of the cases developed generalized seizures throughout their life."</div>
                
                
                <div class="evidence-explanation">Confirms seizures in 68% of cases in the scoping review.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."</div>
                
                
                <div class="evidence-explanation">Lists epileptic seizures among core symptoms of GAMT deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Behavioral abnormality
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000708" target="_blank">
                                Atypical behavior
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000708)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."</div>
                
                
                <div class="evidence-explanation">Identifies autistic behaviour as a core symptom of GAMT deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36856349" target="_blank">PMID:36856349</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia."</div>
                
                
                <div class="evidence-explanation">Lists behavioral problems among the range of symptoms in creatine deficiency disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Autism
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000717" target="_blank">
                                Autism
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000717)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."</div>
                
                
                <div class="evidence-explanation">Identifies autistic behaviour as a recognized symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Movement abnormality
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100022" target="_blank">
                                Abnormality of movement
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100022)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13."</div>
                
                
                <div class="evidence-explanation">Quantifies movement disorder at 13/48 (27%) in the cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."</div>
                
                
                <div class="evidence-explanation">Confirms movement disorders as a recognized symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Abnormality of the globus pallidus
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002453" target="_blank">
                                Abnormal globus pallidus morphology
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002453)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The MRI scan shows an increased signal in the globus pallidus, and the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."</div>
                
                
                <div class="evidence-explanation">Directly describes globus pallidus signal abnormality on MRI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Absent speech
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001344" target="_blank">
                                Absent speech
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001344)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."</div>
                
                
                <div class="evidence-explanation">Limited speech development in untreated cases can progress to absent speech in severe presentations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Involuntary movements
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004305" target="_blank">
                                Involuntary movements
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004305)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."</div>
                
                
                <div class="evidence-explanation">Explicitly lists involuntary movements among associated features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GAMT pathogenic variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."</div>
                
                
                <div class="evidence-explanation">Confirms pathogenic variants in GAMT as the cause.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"23% of the affected cases were of consanguineous marriages, and 7% had affected relatives."</div>
                
                
                <div class="evidence-explanation">Quantifies consanguinity as a risk factor in the scoping review.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase deficiency (GAMT) is an autosomal recessive inborn error of metabolism. A condition that results from a pathogenic variant in the GAMT gene that maps to 19p13.3."</div>
                
                
                <div class="evidence-explanation">Confirms the chromosomal location and autosomal recessive nature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Creatine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Oral creatine monohydrate is the cornerstone of therapy, aimed at repleting systemic and cerebral creatine stores. Typical dosing is approximately 400-800 mg/kg/day. Treatment is associated with improvement of cerebral creatine on MRS and clinical symptom stabilization or improvement, though brain creatine may not fully normalize.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"</div>
                
                
                <div class="evidence-explanation">Directly supports creatine supplementation as effective in increasing cerebral creatine.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Therapy was associated with improvement or stabilization of symptoms in all of the symptomatic cases. The 4 patients treated younger than 9 months had normal or almost normal developmental outcomes."</div>
                
                
                <div class="evidence-explanation">Demonstrates clinical benefit of early creatine-based therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels."</div>
                
                
                <div class="evidence-explanation">Confirms creatine supplementation as a treatment component.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ornithine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Oral L-ornithine is used as a substrate-reduction strategy to inhibit AGAT activity, thereby reducing guanidinoacetate synthesis. Dosing ranges from 100 to 800 mg/kg/day. Ornithine combined with creatine is more effective than creatine alone at reducing GAA levels.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets."</div>
                
                
                <div class="evidence-explanation">Confirms ornithine as a standard treatment component.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"</div>
                
                
                <div class="evidence-explanation">Demonstrates that high-dose ornithine contributes to GAA reduction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels."</div>
                
                
                <div class="evidence-explanation">Confirms ornithine&#39;s role in reducing toxic GAA levels.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Protein/arginine-restricted diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary restriction of protein and/or arginine intake reduces the precursor supply for guanidinoacetate synthesis via AGAT, serving as a substrate-reduction approach. This is typically combined with creatine and ornithine supplementation.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet (250 mg/kg/d l-arginine)."</div>
                
                
                <div class="evidence-explanation">Supports arginine-restricted diet as part of the effective treatment regimen.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment is based on giving creatine supplementation orally and a low-protein diet with restricted arginine and increased ornithine."</div>
                
                
                <div class="evidence-explanation">Confirms low-protein, arginine-restricted diet as a standard treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Sodium benzoate therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Sodium benzoate is used in some treatment protocols to reduce glycine availability, a precursor for guanidinoacetate synthesis. Dosing is approximately 100 mg/kg/day. This reduces the substrate pool available for AGAT, contributing to GAA lowering.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets."</div>
                
                
                <div class="evidence-explanation">Confirms sodium benzoate as a component of treatment protocols.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">GAMT deficiency screening can be incorporated into existing tandem mass spectrometry newborn screening platforms, detecting elevated guanidinoacetate. The Advisory Committee on Heritable Disorders in Newborns and Children recommended addition to the RUSP, accepted in January 2023. Presymptomatic detection enables early treatment initiation before irreversible neurologic damage.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the feasibility of screening, the low number of positive results, the relative ease of diagnosis, and the expected benefit of presymptomatic dietary therapy led to a recommendation from the Advisory Committee on Heritable Disorders in Newborns and Children to the Secretary of Health and Human..."</div>
                
                
                <div class="evidence-explanation">Documents the policy decision to add GAMT deficiency to the RUSP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Anticonvulsant therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Antiepileptic medications are used to manage seizures, which affect approximately 70% of patients. Seizure improvement is often observed with metabolic treatment (creatine supplementation), sometimes allowing reduction of anticonvulsant medications.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This results in improvement of many of the symptoms, especially of the epileptic seizures and the abnormal movements."</div>
                
                
                <div class="evidence-explanation">Notes that treatment improves epileptic seizures, implying anticonvulsant management is part of care.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for affected families covers autosomal recessive inheritance, 25% recurrence risk, carrier testing, prenatal diagnosis, and the importance of premarital genetic testing in populations with high consanguinity rates.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39006040" target="_blank">PMID:39006040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Premarital testing of neurogenetic diseases using whole-exome sequencing is probably a future direction, especially in populations with high consanguinity rates."</div>
                
                
                <div class="evidence-explanation">Supports genetic counseling and carrier testing, particularly in consanguineous populations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene"</div>
                
                
                <div class="evidence-explanation">Autosomal recessive inheritance necessitates genetic counseling for family planning.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Gene therapy (investigational)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001001" target="_blank">
                            MAXO:0001001
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">AAV-based gene therapy expressing human GAMT in hepatocytes is under preclinical development. In a murine model, liver-directed gene therapy achieved pan-hepatic GAMT expression, marked and sustained reduction of GAA, normalization of plasma creatine, increased cerebral and myocardial creatine, and resolution of behavioral abnormalities. CNS-directed AAV9 approaches are also being investigated.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35505663" target="_blank">PMID:35505663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Serial collection of blood demonstrated a marked early and sustained reduction of GAA with normalization of plasma creatine; urinary GAA levels also markedly declined."</div>
                
                
                <div class="evidence-explanation">Shows sustained biochemical correction in the gene therapy mouse model.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35505663" target="_blank">PMID:35505663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"The terminal time point demonstrated marked improvement in cerebral and myocardial creatine levels. In conjunction with the biochemical findings, treated mice gained weight to nearly match their wild-type littermates, while behavioral studies demonstrated resolution of abnormalities"</div>
                
                
                <div class="evidence-explanation">Demonstrates improved cerebral/myocardial creatine and resolved behavioral phenotype with gene therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Guanidinoacetate
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Guanidinoacetate (GAA) is markedly elevated in plasma, urine, CSF, and brain in GAMT deficiency. Elevated GAA is the primary diagnostic biomarker and is considered neurotoxic. It can be detected by tandem mass spectrometry in newborn screening programs.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37465909" target="_blank">PMID:37465909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."</div>
                
                
                <div class="evidence-explanation">Confirms neurotoxic GAA accumulation as a defining feature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."</div>
                
                
                <div class="evidence-explanation">Confirms elevated urinary GAA as a diagnostic marker.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24268530" target="_blank">PMID:24268530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"</div>
                
                
                <div class="evidence-explanation">Documents elevated baseline plasma/CSF GAA that decreases with treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Creatine is depleted in plasma, urine, CSF, and brain. Cerebral creatine deficiency is detectable by proton magnetic resonance spectroscopy (1H-MRS), which shows absent or markedly decreased creatine peak. Brain creatine may not fully normalize even with long-term treatment.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19289269" target="_blank">PMID:19289269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."</div>
                
                
                <div class="evidence-explanation">Confirms low plasma creatine as a diagnostic finding.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges."</div>
                
                
                <div class="evidence-explanation">Shows that even with treatment, brain creatine does not normalize, confirming baseline deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36856349" target="_blank">PMID:36856349</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate methyltransferase deficiency"</div>
                
                
                <div class="evidence-explanation">Confirms low creatine in body fluids as a diagnostic marker.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine on brain MRS
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Proton magnetic resonance spectroscopy (1H-MRS) of the brain shows absent or markedly decreased creatine peak, which serves as a non-invasive diagnostic and monitoring tool for cerebral creatine deficiency.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469086" target="_blank">PMID:38469086</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges."</div>
                
                
                <div class="evidence-explanation">Confirms decreased brain creatine on MRS that improves but does not normalize with treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatinine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Low urinary creatinine reflects the underlying creatine depletion state. Creatine-to-creatinine ratio in urine helps distinguish GAMT deficiency from creatine transporter deficiency.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36856349" target="_blank">PMID:36856349</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate methyltransferase deficiency"</div>
                
                
                <div class="evidence-explanation">Low creatine in body fluids would be accompanied by low creatinine as a downstream metabolite.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Guanidinoacetate Methyltransferase Deficiency
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-28T02:58:52Z&#39;
synonyms:
- GAMT deficiency
- Cerebral creatine deficiency syndrome type 2
- CCDS2
description: &#39;Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive inborn error of creatine biosynthesis
  caused by biallelic pathogenic variants in GAMT (19p13.3). GAMT catalyzes the final step of endogenous creatine synthesis
  by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as the methyl donor. Loss of GAMT activity
  produces systemic and cerebral creatine depletion together with neurotoxic accumulation of guanidinoacetate in biofluids
  and brain. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with intellectual disability,
  severe speech delay, epilepsy, behavioral abnormalities, and movement disorders. Presymptomatic treatment with creatine
  supplementation, ornithine, and dietary arginine restriction substantially improves outcomes, motivating addition to the
  US Recommended Uniform Screening Panel in January 2023. Birth prevalence is estimated at 0.5 to 2 per million live births.

  &#39;
disease_term:
  preferred_term: guanidinoacetate methyltransferase deficiency
  term:
    id: MONDO:0012999
    label: guanidinoacetate methyltransferase deficiency
parents:
- Metabolic Disease
- Inborn error of metabolism
prevalence:
- notes: Birth prevalence is estimated between 0.5 and 2 per million live births. In newborn screening programs, approximately
    1 per 100,000 newborns screen positive. Programmatic detection rates include 1 case in 1.4 million screened in Australia,
    1 case per 321,305 screened in Utah, and 1 case per 759,246 screened in New York.
progression:
- notes: Newborns may appear asymptomatic at birth due to in utero placental creatine transfer. Symptoms first become noticeable
    at a mean of approximately 14 months (range 3-24 months). Without newborn screening, mean age at diagnosis is approximately
    8.5 years (range 9 months to 25 years). Once significant neurologic impairment develops, treatment benefit is limited,
    underscoring the critical window for early intervention. The four patients treated before 9 months of age in a landmark
    cohort had normal or near-normal developmental outcomes.
pathophysiology:
- name: GAMT molecular function deficiency
  description: &#39;Biallelic pathogenic variants in GAMT reduce guanidinoacetate methyltransferase
    catalytic activity.

    &#39;
  genes:
  - preferred_term: GAMT
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Supports GAMT molecular dysfunction as the initiating defect.
  downstream:
  - target: Deficient creatine biosynthesis
    description: Reduced GAMT activity blocks conversion of guanidinoacetate to creatine.
- name: Deficient creatine biosynthesis
  description: &#39;Blocked conversion of guanidinoacetate to creatine causes systemic
    and cerebral creatine depletion, impairing the creatine/phosphocreatine energy
    shuttle needed for rapid ATP regeneration in high-energy-demand tissues.

    &#39;
  biological_processes:
  - preferred_term: creatine biosynthetic process
    term:
      id: GO:0006601
      label: creatine biosynthetic process
  - preferred_term: phosphocreatine metabolic process
    term:
      id: GO:0006603
      label: phosphocreatine metabolic process
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual
      disability, seizures, speech disturbances and movement disorders.
    explanation: Confirms cerebral creatine depletion and GAA accumulation as the dual mechanism of disease.
  downstream:
  - target: Guanidinoacetate neurotoxicity
- name: Guanidinoacetate neurotoxicity
  description: &#39;Guanidinoacetate (GAA) accumulates in brain, CSF, blood, and urine due to blocked conversion to creatine.
    GAA is neurotoxic and may alter inhibitory neurotransmission, compounding the effects of cerebral energy deficiency.

    &#39;
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual
      disability, seizures, speech disturbances and movement disorders.
    explanation: Confirms GAA accumulation as a contributor to the neurological phenotype.
  - reference: PMID:35505663
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Along with low creatine levels, guanidinoacetic acid (GAA) toxicity has been implicated in the pathophysiology
      of the disorder.
    explanation: Supports GAA toxicity as a distinct pathophysiological mechanism beyond creatine deficiency alone.
  downstream:
  - target: Impaired neuronal energy homeostasis
- name: Impaired neuronal energy homeostasis
  description: &#39;The creatine/phosphocreatine system serves as a critical ATP buffer and energy shuttle in neurons. Creatine
    deficiency impairs rapid ATP regeneration during fluctuating energy demands, contributing to neurodevelopmental dysfunction,
    seizure susceptibility, and disrupted neurite outgrowth and neurotransmission.

    &#39;
  biological_processes:
  - preferred_term: ATP metabolic process
    term:
      id: GO:0046034
      label: ATP metabolic process
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis
      due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Cerebral creatine deficiency directly implies impaired neuronal energy homeostasis via loss of the creatine/phosphocreatine
      shuttle.
  - reference: PMID:35505663
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Creatine deficiency disorders are inborn errors of creatine metabolism, an energy homeostasis molecule.
    explanation: Explicitly identifies creatine as an energy homeostasis molecule, supporting the energy-deficit mechanism.
phenotypes:
- name: Global developmental delay
  frequency: VERY_FREQUENT
  description: &#39;Developmental delay/intellectual disability is the most consistent feature, present in 44 of 48 patients (92%)
    in the landmark cohort, 100% in a 2023 review, and 84% in a 53-case scoping review.

    &#39;
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems
      as the most affected domains was present in 44 participants
    explanation: Quantifies developmental delay at 44/48 (92%) in the landmark GAMT deficiency cohort.
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 84% of the cases expressed a form of developmental delay.
    explanation: Confirms high frequency of developmental delay in a scoping review of 53 cases.
- name: Intellectual disability
  frequency: VERY_FREQUENT
  description: &#39;Intellectual disability ranges from mild to severe and is a hallmark feature. Severity correlates with age
    at treatment initiation, with patients treated before 9 months achieving normal or near-normal cognitive outcomes.

    &#39;
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median age at treatment initiation was 25.5 and 39 months in patients with mild and moderate DD/ID, respectively,
      and 11 years in patients with severe DD/ID.
    explanation: Demonstrates correlation between treatment timing and severity of intellectual disability.
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 43% of the cases had intellectual disabilities and mental retardation that affected their learning process; most
      cases required special care.
    explanation: Supports intellectual disability as a major feature requiring special care.
- name: Delayed speech and language development
  frequency: VERY_FREQUENT
  description: &#39;Speech and language delay is particularly prominent and is often the most affected developmental domain. Many
    patients have severely limited or absent speech.

    &#39;
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The symptoms and signs are reviewed, emphasising that delayed language development is a particular feature.
    explanation: Identifies delayed language development as a particularly prominent feature of GAMT deficiency.
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems
      as the most affected domains was present in 44 participants
    explanation: Confirms speech/language delay as one of the most affected domains.
- name: Seizures
  frequency: VERY_FREQUENT
  description: &#39;Epilepsy occurs in approximately 70-73% of patients. Seizures may reflect both cerebral energy instability
    and direct GAA effects on inhibitory neurotransmission. Seizure control often improves with
    creatine supplementation.

    &#39;
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems
      as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder
      in 13.
    explanation: Quantifies epilepsy at 35/48 (73%) in the landmark cohort.
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 68% of the cases developed generalized seizures throughout their life.
    explanation: Confirms seizures in 68% of cases in the scoping review.
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Lists epileptic seizures among core symptoms of GAMT deficiency.
- name: Behavioral abnormality
  frequency: FREQUENT
  description: &#39;Behavioral disturbances are common and include autistic features, self-mutilation, hyperactivity, and other
    severe behavioral disorders. Behavioral problems were noted in approximately 75% in a clinical review.

    &#39;
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Identifies autistic behaviour as a core symptom of GAMT deficiency.
  - reference: PMID:36856349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures,
      movement disorder, behavioral problems, and hypotonia.
    explanation: Lists behavioral problems among the range of symptoms in creatine deficiency disorders.
- name: Movement abnormality
  frequency: OCCASIONAL
  description: &#39;Movement disorders including dystonia and ataxia occur in approximately 27-30% of patients. In the landmark
    cohort, movement disorder was documented in 13 of 48 patients.

    &#39;
  phenotype_term:
    preferred_term: Abnormality of movement
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems
      as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder
      in 13.
    explanation: Quantifies movement disorder at 13/48 (27%) in the cohort.
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Confirms movement disorders as a recognized symptom.
- name: Muscular hypotonia
  frequency: FREQUENT
  description: &#39;Hypotonia is a common clinical feature noted in the untreated presentation of GAMT deficiency.

    &#39;
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech
      development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Lists hypotonia as an associated feature of untreated GAMT deficiency.
  - reference: PMID:36856349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures,
      movement disorder, behavioral problems, and hypotonia.
    explanation: Confirms hypotonia among the symptom spectrum.
- name: Autism
  frequency: OCCASIONAL
  description: &#39;Autistic features and autistic-like behavior are reported in a subset of patients with GAMT deficiency.

    &#39;
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Identifies autistic behaviour as a recognized symptom.
- name: Abnormality of the globus pallidus
  frequency: OCCASIONAL
  description: &#39;MRI shows increased signal in the globus pallidus, and T2 hyperintensities in the basal ganglia have been
    reported.

    &#39;
  phenotype_term:
    preferred_term: Abnormal globus pallidus morphology
    term:
      id: HP:0002453
      label: Abnormal globus pallidus morphology
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The MRI scan shows an increased signal in the globus pallidus, and the diagnosis is confirmed by finding increased
      guanidinoacetate in the urine and a low plasma creatine.
    explanation: Directly describes globus pallidus signal abnormality on MRI.
- name: Absent speech
  frequency: OCCASIONAL
  description: &#39;In severe cases, patients may have absent or extremely limited speech production, representing the severe
    end of the speech/language impairment spectrum.

    &#39;
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech
      development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Limited speech development in untreated cases can progress to absent speech in severe presentations.
- name: Involuntary movements
  frequency: OCCASIONAL
  description: &#39;Involuntary movements are described as a feature of untreated GAMT deficiency, distinct from the broader movement
    disorder category.

    &#39;
  phenotype_term:
    preferred_term: Involuntary movements
    term:
      id: HP:0004305
      label: Involuntary movements
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech
      development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Explicitly lists involuntary movements among associated features.
biochemical:
- name: Guanidinoacetate
  presence: INCREASED
  context: &#39;Guanidinoacetate (GAA) is markedly elevated in plasma, urine, CSF, and brain in GAMT deficiency. Elevated GAA
    is the primary diagnostic biomarker and is considered neurotoxic. It can be detected by tandem mass spectrometry in newborn
    screening programs.

    &#39;
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis
      due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Confirms neurotoxic GAA accumulation as a defining feature.
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine.
    explanation: Confirms elevated urinary GAA as a diagnostic marker.
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation
      with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Documents elevated baseline plasma/CSF GAA that decreases with treatment.
- name: Creatine
  presence: DECREASED
  context: &#39;Creatine is depleted in plasma, urine, CSF, and brain. Cerebral creatine deficiency is detectable by proton magnetic
    resonance spectroscopy (1H-MRS), which shows absent or markedly decreased creatine peak. Brain creatine may not fully
    normalize even with long-term treatment.

    &#39;
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine.
    explanation: Confirms low plasma creatine as a diagnostic finding.
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly
      over time, but did not reach age matched control ranges.
    explanation: Shows that even with treatment, brain creatine does not normalize, confirming baseline deficiency.
  - reference: PMID:36856349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate
      methyltransferase deficiency
    explanation: Confirms low creatine in body fluids as a diagnostic marker.
- name: Creatine on brain MRS
  presence: DECREASED
  context: &#39;Proton magnetic resonance spectroscopy (1H-MRS) of the brain shows absent or markedly decreased creatine peak,
    which serves as a non-invasive diagnostic and monitoring tool for cerebral creatine deficiency.

    &#39;
  evidence:
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly
      over time, but did not reach age matched control ranges.
    explanation: Confirms decreased brain creatine on MRS that improves but does not normalize with treatment.
- name: Creatinine
  presence: DECREASED
  notes: &#39;Low creatinine in urine may also be observed since creatinine is derived from creatine. Urine creatine-to-creatinine
    ratio may be informative for differential diagnosis within cerebral creatine deficiency syndromes.

    &#39;
  context: &#39;Low urinary creatinine reflects the underlying creatine depletion state. Creatine-to-creatinine ratio in urine
    helps distinguish GAMT deficiency from creatine transporter deficiency.

    &#39;
  evidence:
  - reference: PMID:36856349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate
      methyltransferase deficiency
    explanation: Low creatine in body fluids would be accompanied by low creatinine as a downstream metabolite.
genetic:
- name: GAMT pathogenic variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:37465909
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis
        due to pathogenic variants in the GAMT gene
      explanation: Explicitly states autosomal recessive inheritance.
    - reference: PMID:19289269
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The condition is inherited in an autosomal recessive manner, and mutations in the GAMT gene severely affect
        the activity of guanidinoacetate.
      explanation: Confirms autosomal recessive inheritance pattern.
  features: &#39;GAMT deficiency is caused by biallelic pathogenic variants in GAMT (chromosome 19p13.3), encoding guanidinoacetate
    N-methyltransferase. The enzyme catalyzes methylation of guanidinoacetate to creatine using S-adenosylmethionine as the
    methyl donor. Loss-of-function variants result in deficient enzymatic activity, leading to creatine depletion and GAA
    accumulation. Consanguinity is a risk factor; 23% of affected cases in one scoping review were from consanguineous marriages.
    Countries with high consanguinity rates such as Saudi Arabia may have higher prevalence.

    &#39;
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis
      due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Confirms pathogenic variants in GAMT as the cause.
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 23% of the affected cases were of consanguineous marriages, and 7% had affected relatives.
    explanation: Quantifies consanguinity as a risk factor in the scoping review.
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase deficiency (GAMT) is an autosomal recessive inborn error of metabolism. A
      condition that results from a pathogenic variant in the GAMT gene that maps to 19p13.3.
    explanation: Confirms the chromosomal location and autosomal recessive nature.
treatments:
- name: Creatine supplementation
  description: &#39;Oral creatine monohydrate is the cornerstone of therapy, aimed at repleting systemic and cerebral creatine
    stores. Typical dosing is approximately 400-800 mg/kg/day. Treatment is associated with improvement of cerebral creatine
    on MRS and clinical symptom stabilization or improvement, though brain creatine may not fully normalize.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation
      with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Directly supports creatine supplementation as effective in increasing cerebral creatine.
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Therapy was associated with improvement or stabilization of symptoms in all of the symptomatic cases. The 4 patients
      treated younger than 9 months had normal or almost normal developmental outcomes.
    explanation: Demonstrates clinical benefit of early creatine-based therapy.
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake
      and supplementation of ornithine for reduction of toxic GAA levels.
    explanation: Confirms creatine supplementation as a treatment component.
- name: Ornithine supplementation
  description: &#39;Oral L-ornithine is used as a substrate-reduction strategy to inhibit AGAT activity, thereby reducing guanidinoacetate
    synthesis. Dosing ranges from 100 to 800 mg/kg/day. Ornithine combined with creatine is more effective than creatine alone
    at reducing GAA levels.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate
      and protein/arginine restricted diets.
    explanation: Confirms ornithine as a standard treatment component.
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation
      with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Demonstrates that high-dose ornithine contributes to GAA reduction.
  - reference: PMID:38469086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake
      and supplementation of ornithine for reduction of toxic GAA levels.
    explanation: Confirms ornithine&#39;s role in reducing toxic GAA levels.
- name: Protein/arginine-restricted diet
  description: &#39;Dietary restriction of protein and/or arginine intake reduces the precursor supply for guanidinoacetate synthesis
    via AGAT, serving as a substrate-reduction approach. This is typically combined with creatine and ornithine supplementation.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation
      with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet (250 mg/kg/d
      l-arginine).
    explanation: Supports arginine-restricted diet as part of the effective treatment regimen.
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment is based on giving creatine supplementation orally and a low-protein diet with restricted arginine
      and increased ornithine.
    explanation: Confirms low-protein, arginine-restricted diet as a standard treatment.
- name: Sodium benzoate therapy
  description: &#39;Sodium benzoate is used in some treatment protocols to reduce glycine availability, a precursor for guanidinoacetate
    synthesis. Dosing is approximately 100 mg/kg/day. This reduces the substrate pool available for AGAT, contributing to
    GAA lowering.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:24268530
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate
      and protein/arginine restricted diets.
    explanation: Confirms sodium benzoate as a component of treatment protocols.
- name: Newborn screening
  description: &#39;GAMT deficiency screening can be incorporated into existing tandem mass spectrometry newborn screening platforms,
    detecting elevated guanidinoacetate. The Advisory Committee on Heritable Disorders in Newborns and Children recommended
    addition to the RUSP, accepted in January 2023. Presymptomatic detection enables early treatment initiation before irreversible
    neurologic damage.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the feasibility of screening, the low number of positive results, the relative ease of diagnosis, and the expected
      benefit of presymptomatic dietary therapy led to a recommendation from the Advisory Committee on Heritable Disorders
      in Newborns and Children to the Secretary of Health and Human Services that GAMT deficiency be added to the Recommended
      Uniform Screening Panel. This recommendation was accepted in January 2023.
    explanation: Documents the policy decision to add GAMT deficiency to the RUSP.
- name: Anticonvulsant therapy
  description: &#39;Antiepileptic medications are used to manage seizures, which affect approximately 70% of patients. Seizure
    improvement is often observed with metabolic treatment (creatine supplementation), sometimes allowing reduction of anticonvulsant
    medications.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:19289269
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This results in improvement of many of the symptoms, especially of the epileptic seizures and the abnormal movements.
    explanation: Notes that treatment improves epileptic seizures, implying anticonvulsant management is part of care.
- name: Genetic counseling
  description: &#39;Genetic counseling for affected families covers autosomal recessive inheritance, 25% recurrence risk, carrier
    testing, prenatal diagnosis, and the importance of premarital genetic testing in populations with high consanguinity rates.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:39006040
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Premarital testing of neurogenetic diseases using whole-exome sequencing is probably a future direction, especially
      in populations with high consanguinity rates.
    explanation: Supports genetic counseling and carrier testing, particularly in consanguineous populations.
  - reference: PMID:37465909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis
      due to pathogenic variants in the GAMT gene
    explanation: Autosomal recessive inheritance necessitates genetic counseling for family planning.
- name: Gene therapy (investigational)
  description: &#39;AAV-based gene therapy expressing human GAMT in hepatocytes is under preclinical development. In a murine
    model, liver-directed gene therapy achieved pan-hepatic GAMT expression, marked and sustained reduction of GAA, normalization
    of plasma creatine, increased cerebral and myocardial creatine, and resolution of behavioral abnormalities. CNS-directed
    AAV9 approaches are also being investigated.

    &#39;
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  notes: &#39;Gene therapy for GAMT deficiency remains investigational and is not yet available clinically. Both liver-directed
    and CNS-directed AAV vector approaches are being explored in preclinical models.

    &#39;
  evidence:
  - reference: PMID:35505663
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Serial collection of blood demonstrated a marked early and sustained reduction of GAA with normalization of plasma
      creatine; urinary GAA levels also markedly declined.
    explanation: Shows sustained biochemical correction in the gene therapy mouse model.
  - reference: PMID:35505663
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The terminal time point demonstrated marked improvement in cerebral and myocardial creatine levels. In conjunction
      with the biochemical findings, treated mice gained weight to nearly match their wild-type littermates, while behavioral
      studies demonstrated resolution of abnormalities
    explanation: Demonstrates improved cerebral/myocardial creatine and resolved behavioral phenotype with gene therapy.
notes: &#39;GAMT deficiency is one of three cerebral creatine deficiency syndromes (CCDS), alongside AGAT deficiency (GATM mutations)
  and creatine transporter deficiency (SLC6A8 mutations). GAMT deficiency is distinguished by elevated guanidinoacetate (rather
  than low GAA in AGAT deficiency or elevated urine creatine-to-creatinine ratio in SLC6A8 deficiency). Treatment is most
  effective when initiated presymptomatically, as demonstrated by normal/near-normal outcomes in the four patients treated
  before 9 months in the landmark 48-patient cohort. This underscores the importance of newborn screening, which was added
  to the US RUSP in January 2023. Long-term monitoring with 1H-MRS shows that brain creatine may increase with treatment but
  typically does not reach age-matched control ranges, motivating ongoing development of curative gene therapy approaches.
  Failure to thrive and feeding difficulties are reported clinically in some patients but are not retained as an evidence-backed
  phenotype assertion in this entry.

  &#39;
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Guanidinoacetate_Methyltransferase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>